Literature DB >> 17005757

MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples.

Evguenia S Svarovskaia1, Michael J Moser, Andrew S Bae, James R Prudent, Michael D Miller, Katyna Borroto-Esoda.   

Abstract

We report a real-time PCR assay capable of detecting drug-resistant human immunodeficiency virus type 1 reverse transcriptase K65R mutant virus at a level of 0.5% in polymorphic patient plasma specimens. Fifty-three treatment-naïve and 20 treatment-experienced specimens were successfully genotyped with the new method. Results were in agreement with population sequencing and the labor-intensive single-genome sequencing method.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17005757      PMCID： PMC1698293          DOI： 10.1128/JCM.01512-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  24 in total

1.  Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission.

Authors:  S Palmer; V Boltz; N Martinson; F Maldarelli; G Gray; J McIntyre; J Mellors; L Morris; J Coffin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-25       Impact factor: 11.205

2.  Analysis of heterogeneous viral populations by direct DNA sequencing.

Authors:  T Leitner; E Halapi; G Scarlatti; P Rossi; J Albert; E M Fenyö; M Uhlén
Journal:  Biotechniques       Date:  1993-07       Impact factor: 1.993

3.  Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program.

Authors:  Rob Schuurman; Donald Brambilla; Tom de Groot; Diana Huang; Sally Land; James Bremer; Ireen Benders; Charles A B Boucher
Journal:  AIDS Res Hum Retroviruses       Date:  2002-03-01       Impact factor: 2.205

4.  Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group.

Authors:  P R Harrigan; C Stone; P Griffin; I Nájera; S Bloor; S Kemp; M Tisdale; B Larder
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

5.  Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.

Authors:  Nicolas A Margot; Erica Isaacson; Ian McGowan; Andrew K Cheng; Robert T Schooley; Michael D Miller
Journal:  AIDS       Date:  2002-06-14       Impact factor: 4.177

6.  A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.

Authors:  J Gerardo García-Lerma; Hamish MacInnes; Diane Bennett; Patrick Reid; Soumya Nidtha; Hillard Weinstock; Jonathan E Kaplan; Walid Heneine
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

7.  Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

Authors:  S G Deeks; T Wrin; T Liegler; R Hoh; M Hayden; J D Barbour; N S Hellmann; C J Petropoulos; J M McCune; M K Hellerstein; R M Grant
Journal:  N Engl J Med       Date:  2001-02-15       Impact factor: 91.245

8.  Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience.

Authors:  Anita Shet; Leslie Berry; Hiroshi Mohri; Saurabh Mehandru; Chris Chung; Alexandria Kim; Patrick Jean-Pierre; Christine Hogan; Viviana Simon; Daniel Boden; Martin Markowitz
Journal:  J Acquir Immune Defic Syndr       Date:  2006-04-01       Impact factor: 3.731

Review 9.  Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance.

Authors:  Joel E Gallant; Peter Z Gerondelis; Mark A Wainberg; Nancy S Shulman; Richard H Haubrich; Marty St Clair; Ernest R Lanier; Nicholas S Hellmann; Douglas D Richman
Journal:  Antivir Ther       Date:  2003-12

10.  Complementation in cells cotransfected with a mixture of wild-type and mutant human immunodeficiency virus (HIV) influences the replication capacities and phenotypes of mutant variants in a single-cycle HIV resistance assay.

Authors:  Hongmei Mo; Liangjun Lu; Ron Pithawalla; Dale J Kempf; Akhteruzzaman Molla
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948
View more
  9 in total

1.  Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.

Authors:  Kristen N Andreatta; Derrick D Goodman; Michael D Miller; Kirsten L White
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

2.  Low-frequency nevirapine resistance at multiple sites may predict treatment failure in infants on nevirapine-based treatment.

Authors:  Dara A Lehman; Dalton C Wamalwa; Connor O McCoy; Frederick A Matsen; Agnes Langat; Bhavna H Chohan; Sarah Benki-Nugent; Rebecca Custers-Allen; Frederic D Bushman; Grace C John-Stewart; Julie Overbaugh
Journal:  J Acquir Immune Defic Syndr       Date:  2012-07-01       Impact factor: 3.731

3.  Highly sensitive and quantitative detection of the H274Y oseltamivir resistance mutation in seasonal A/H1N1 influenza virus.

Authors:  Darwin J Operario; Michael J Moser; Kirsten St George
Journal:  J Clin Microbiol       Date:  2010-07-28       Impact factor: 5.948

4.  Detection of cytomegalovirus in whole blood using three different real-time PCR chemistries.

Authors:  Erica Vincent; Zhengming Gu; Markus Morgenstern; Candace Gibson; Jianmin Pan; Randall T Hayden
Journal:  J Mol Diagn       Date:  2008-12-12       Impact factor: 5.568

5.  Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.

Authors:  Kristen N Andreatta; Michael D Miller; Kirsten L White
Journal:  Antimicrob Agents Chemother       Date:  2015-11-16       Impact factor: 5.191

6.  Detection and quantification of hepatitis C virus (HCV) by MultiCode-RTx real-time PCR targeting the HCV 3' untranslated region.

Authors:  Elizabeth K Mulligan; J J Germer; Max Q Arens; Krista L D'Amore; Adrian Di Bisceglie; Nathan A Ledeboer; Michael J Moser; Andrew C Newman; Andy K O'Guin; Paul D Olivo; Diane S Podzorski; Kimberly A Vaughan; Joseph D Yao; Slava A Elagin; Scott C Johnson
Journal:  J Clin Microbiol       Date:  2009-06-17       Impact factor: 5.948

7.  Optimization of an unnatural base pair toward natural-like replication.

Authors:  Young Jun Seo; Gil Tae Hwang; Phillip Ordoukhanian; Floyd E Romesberg
Journal:  J Am Chem Soc       Date:  2009-03-11       Impact factor: 15.419

8.  Allele-specific real-time PCR system for detection of subpopulations of genotype 1a and 1b hepatitis C NS5B Y448H mutant viruses in clinical samples.

Authors:  Andrew S Bae; Karin S Ku; Michael D Miller; Hongmei Mo; Evguenia S Svarovskaia
Journal:  J Clin Microbiol       Date:  2011-06-29       Impact factor: 5.948

9.  APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon.

Authors:  Andrew E Armitage; Koen Deforche; Chih-Hao Chang; Edmund Wee; Beatrice Kramer; John J Welch; Jan Gerstoft; Lars Fugger; Andrew McMichael; Andrew Rambaut; Astrid K N Iversen
Journal:  PLoS Genet       Date:  2012-03-22       Impact factor: 5.917
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.